Menu
Your Cart

News

Latest Updates on LinkedIn

News

February 1, 2024

[Cancer Cell] Tumor- and circulating-free DNA methylation identifies clinically relevant small cell lung cancer subtypes

Small cell lung cancer (SCLC) is an aggressive malignancy composed of distinct transcriptional subtypes, but implementing subtyping in the clinic has remained challenging, particularly due to limited tissue availability.  This new clinical study, led by scientists from MD Anderson Cancer Center and published in Cancer Cell (journal impact factor = 50.3), establishes that tumor and cfDNA methylation can be used to identify SCLC subtypes and might guide precision SCLC therapy.

Apostle Minimax cfDNA kit is one of the critical commercial assays listed in this article.    Congratulations to this clinical research team. To date, the Apostle Minimax technology has been used in 2 articles published in Nature Communications, 2 in Nature Medicine, 1 in Science Translational Medicine, 1 in PNAS, and over 60 scientific articles by over 60 international research and clinical teams in different journals.  

January 2, 2024

[Nature Communications] Terminal modifications independent cell-free RNA sequencing enables sensitive early cancer detection and classification

Cell-free RNAs (cfRNAs) offer an opportunity to detect diseases from a transcriptomic perspective, however, existing techniques have fallen short in generating a comprehensive cell-free transcriptome profile.  Nature Communications just published a clinical study that includes transcriptome-wide characterizations in 165 lung cancer, 30 breast cancer, 37 colorectal cancer, 55 gastric cancer, 15 liver cancer, and 133 cancer-free participants and demonstrates cfRNA's ability to identify transcriptomic changes occurring in early-stage tumors.  The study uses the Apostle Minimax cfRNA technology. This study sets the stage for in-depth study of the cfRNA repertoire and highlights the value of cfRNAs as cancer biomarkers in clinical applications.  

Congratulations to this clinical research team. To date, the Apostle Minimax technology has been used in 2 articles published in Nature Communications, 2 in Nature Medicine, 1 in Science Translational Medicine, 1 in PNAS, and over 50 scientific articles by over 60 international research and clinical teams in different journals.  

April 10, 2023

[Nature Communications] Integrative modeling of tumor genomes and epigenomes for enhanced cancer diagnosis by cell-free DNA

Nature Communications just published a clinical study, including 2125 cancer patients, 9 cancer types, using the Apostle Minimax cfDNA technology. This study demonstrates the ability of its model to detect early-stage cancers using cfDNA, including those of pancreatic origin, with high sensitivity that is comparable to that of late-stage detection.  Congratulations to this clinical research team. To date, the Apostle Minimax cfDNA technology has been used in 2 articles published in Nature Medicine, 1 in Nature Communications, 1 in Science Translational Medicine, 1 in PNAS, and over 50 scientific articles in different journals.  
 ....read more

November 23, 2022

[Science Translational Medicine] Simultaneous analysis of mutations and methylations in circulating cell-free DNA for hepatocellular carcinoma detection

With the help of Apostle MiniMax cfDNA Isolation Technology, another recent independent clinical study demonstrated  the successful clinical utility and validity of the circulating cell-free DNA (cfDNA) analysis for hepatocellular carcinoma (HCC) detection with high sensitivity and specificity, published in Science Translational Medicine.  In this clinical study, "cfDNA was extracted from the plasma samples using the Apostle MiniMax cfDNA isolation kit (C43468, Apostle)". Congratulations to this clinical research team!   ....read more

August 18, 2022

[Nature Medicine] Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results

Apostle MiniMax Technology contributed to a new independent clinical study, just published in Nature Medicine by a joint clinical team from Gritstone, Columbia University Medical Center, Mayo Clinic, MSKCC, MD Anderson, etc, titled "Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results". In this phase I clinical trial, "Exploratory biomarker analyses showed decreased circulating tumor DNA (ctDNA) in patients with prolonged OS... cfDNA was extracted from the entire plasma volume of a single draw using the Apostle MiniMax cfDNA Isolation kit (ApostleBio) ". Congratulations to this clinical research team!   ....read more

June 14, 2022

[Frontiers in Oncology] Clinical Study Supports the Use of Liquid Biopsy for Early Diagnosis and Monitoring of Patients with Myeloid Neoplasms

Using Apostle MiniMax cfDNA Isolation Technology a recent clinical study in 2821 myeloid or lymphoid neoplasm patients shows that liquid biopsy using targeted NGS is reliable in detecting chromosomal structural abnormalities in myeloid neoplasms. The study supports the use of liquid biopsy for early diagnosis and monitoring of patients with myeloid neoplasms.     ....read more

April 11, 2022

[Nature Medicine] Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial

Apostle MiniMax Technology is cited by an independent clinical study, published in Nature Medicine, studying safety and tolerability of AAV8 delivery of a broadly neutralizing antibody.  In this study, plasma AAV8-VRC07 plasmid DNA was measured by extracting DNA from plasma, concentrating and then using a real-time PCR assay to measure a 103 base sequence spanning the junction of the IgG heavy chain sequence and F2A insert. DNA was extracted from serum using an Apostle MiniMax High Efficiency cfDNA Isolation Kit. Congratulations to this clinical research team!   ....read more

Jan 28, 2022

[SLAS Technology] Performance of Apostle Technology Independently Validated

A recent independent study conducted by scientists from Johns Hopkins University and University of Pittsburgh, published in a peer-reviewed journal SLAS Technology, showed that, "(Page 6, Figure 4) Most notably, the Apostle particles outperformed all others, achieving almost 2-fold higher recovery yields than the particles supplied in the X kit".       ....read more

Aug 30, 2021

Apostle Inc Apostle Diagnostics Laboratory Receives Accreditation from College of American Pathologists

The Accreditation Committee of the College of American Pathologists (CAP) has awarded accreditation to Apostle Inc Apostle Diagnostics Laboratory, San Jose, California based on results of a recent on-site inspection as part of the CAP's Accreditation Programs.     ....read more

Apr 12, 2021

Apostle RNA Extraction Method is Included in a US FDA EUA Authorized SARS-CoV-2 Molecular Diagnostic Test: Fulgent COVID-19 by RT-PCT Test

Apostle Inc is pleased to announce that the company’s Apostle RNA Extraction Method is included in the recent US FDA EUA authorization of a SARS-CoV-2 Molecular Diagnostic Test: Fulgent COVID-19 by RT-PCT Test, as reagent and system used with the FDA EUA authorized test.      ....read more

Feb 2, 2021

[PNAS] Apostle MiniMax Technology In Novel Liquid Biopsy Method for Detecting and Monitoring Colon Cancer, Published in PNAS

Apostle Inc is pleased to announce that the company’s Apostle MiniMax technology is used in the recent development of a novel liquid biopsy method for efficient detection and post-surgical monitoring of colon cancer, capable of quantitative analysis of plasma samples with as little as 0.05% tumor DNA, published in PNAS.      ....read more

Oct 1, 2020

Apostle Inc Releases an Application Note on the Apostle COVID-19 Viral RNA Extraction System

Apostle Inc is pleased to release an Application Note on the Apostle COVID-19 Viral RNA Extraction System, applied in the effective detection of SARS-CoV-2 in over 1 million clinical samples by our clients. Using Apostle system, limit of Detection (LoD) of the downstream detection system of our customer is documented at 3.6 NDU/uL published on the FDA website. The sensitivity and specificity is 99.9% and 99.9% at 3 copies/uL, respectively, published on our customer’s website.  ....read more

Sept 7, 2020

Apostle Inc’s MiniEnrich Technology is Published at Royal Society of Chemistry’s Analyst

Apostle Inc is pleased to announce that the company’s original technology, termed the Apostle MiniEnrich Technology, is published at Royal Society of Chemistry’s Analyst on Sept 7, 2020, vol 145, issue 17, pp 5733-5739, and is selected as the inside front cover story.   ....read more

Sept 3, 2020

Apostle Inc Appoints Charles (Buck) Strom to Board of Advisors

Apostle Inc is pleased to announce the appointment of Charles (Buck) Strom, MD, PhD, FAAP, FACMG, HCLD, as a new member to its Board of Advisors.   ....read more

Feb 13, 2020

Apostle Inc to Present at the 5th Annual Liquid Biopsy Summit

Apostle Inc is pleased to announce that the company is going to present at the 5th Liquid Biopsy Summit, to take place in Seattle, WA on June 15-17, 2020. David Ge, CEO of Apostle, will discuss Apostle MiniEnrich, a novel method for enrichment of short DNA fragments for NIPT and oncology applications.   ....read more

Jan 27, 2020

Apostle Inc Appoints Antonius ‘Toni’ Schuh to Board of Advisors

Apostle Inc is pleased to announce the appointment of Antonius ‘Toni’ Schuh, PhD - a successful serial entrepreneur and founder in the life sciences industries as CEOs of 5 companies with 3 IPOs - as a new member to its Board of Advisors.    ....read more

Jan 23, 2020

Apostle Inc Presents at the PMWC 2020

Apostle Inc presents at the Precision Medicine World Conference 2020 held in Santa Clara, California.   ....read more

Jan 15, 2020

Apostle Inc Appoints Eric D. Masingale as VP of Business Operations

Apostle Inc is pleased to announce the appointment of Mr. Eric D. Masingale as its Vice President of Business Operations.   ....read more

May 24, 2019

Apostle Inc Completes Series A Financing Led by ShangBay Capital

Apostle Inc is pleased to announce the completion of its series A financing.   ....read more

Apr 16, 2019

Apostle Inc Obtains ISO13485:2016 & ISO9001:2015 Certification

Apostle Inc is pleased to receive the Certificates of Conformance to certify its Quality Management System.    ....read more

Feb 28, 2019

Apostle Inc. Enters Partnership with Beckman Coulter Life Sciences

Apostle Inc is pleased to announce an exclusive partnership with Beckman Coulter, a world leader in Life Sciences, for Apostle MiniMax(TM) High Efficiency Cell-Free DNA Isolation Kit.    ....read more

Sept 28, 2018

Apostle's China Manufacturing Facility Obtains ISO9001:2015 Certification

Apostle's manufacturing facility located in Shenzhen, China obtains ISO9001:2015 certification.     ....read more

Apr 3, 2018

Apostle is Elected into the Stanford University StartX Accelerator Program (Summer 2018 session)

Apostle is elected into the StartX Accelerator Program (Summer 2018 session), one of the most pretigeous accelerator programs in the Silicon Valley.     ....read more

Feb 12, 2018

Apostle Inc Appoints Alexander Hartemink, PhD at Duke University to Scientific Advisory Board

Apostle Inc is pleased to announce the appointment of Alexander J. Hartemink, PhD as a new member to its Scientific Advisory Board.     ....read more

Jan 31, 2018

Apostle Inc Appoints David B. Goldstein, PhD at Columbia University to Scientific Advisory Board

Apostle Inc is pleased to announce the appointment of David B. Goldstein, PhD as a new member to its Scientific Advisory Board.    ....read more

Sept 1, 2017

Apostle Inc Appoints Director of Oncology Research at Stanford University to Scientific Advisory Board

Apostle Inc is pleased to announce the appointment of Dean W. Felsher, MD, PhD as a new member to its Scientific Advisory Board. Dr. Felsher is Professor of Medicine in Departments of Oncology and Pathology at Stanford University School of Medicine. He is Director of Stanford Translational Research and Applied Medicine (TRAM) as well as Director of Oncology Research, Division of Oncology at Stanford.    ....read more

Jun 16, 2017

Apostle Announces New Board Member And Advisors

Apostle Inc is pleased to announce the appointment of William Dai, MBA as a new member to its Board of Directors, and Charles Cantor, PhD and Hongyu Zhao, PhD as new members to its Advisory Board.   ....read more

Mar 28, 2017

Apostle Inc is Founded

Apostle Inc, a biotechnology company focusing on liquid biopsy, is founded in the Silicon Valley.   ....read more

 

A new clinical study, led by scientists from MD Anderson Cancer Center and published in Cancer Cell (journal impact factor = 50.3), shows that tumor and cfDNA methylation can be used to identify SCLC subtypes and might guide precision SCLC therapy. Apostle MiniMax cfDNA kit is one of the critical commercial assays listed in this article. Congratulations to this clinical research team. To date, the Apostle MiniMax technology has been used in 2 articles published in Nature Communications, 2 in Nature Medicine, 1 in Science Translational Medicine, 1 in PNAS, and over 60 scientific articles by over 60 international research and clinical teams in different journals.